Literature DB >> 16523307

Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis.

P Mahy1, M De Bast, J Gillart, D Labar, V Grégoire.   

Abstract

In the framework of the preclinical validation of the hypoxic tracer [(18)F]EF3, a comparison was performed between uptake of [(18)F]EF3 and EF5 adducts detected by immunofluorescence in MCa-4, FSA, FSAII, Sa-NH and NFSA tumour-bearing mice. Mice were allowed to breath carbogen (5% CO(2), 95% O(2)), 21% oxygen or 10% oxygen. A significant correlation (r (2)=0.57; p<0.01) was found between the [(18)F]EF3 tumour-to-muscle ratio and the fluorescence intensity of EF5.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16523307     DOI： 10.1007/s00259-005-0049-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  8 in total

1.  Synthesis of [18F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia.

Authors:  O Josse; D Labar; B Georges; V Grégoire; J Marchand-Brynaert
Journal:  Bioorg Med Chem       Date:  2001-03       Impact factor: 3.641

2.  Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes.

Authors:  L Milas; N Hunter; K Mason; H R Withers
Journal:  Cancer Res       Date:  1974-01       Impact factor: 12.701

Review 3.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.

Authors:  M Höckel; P Vaupel
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

4.  Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells.

Authors:  J S Rasey; Z Grunbaum; S Magee; N J Nelson; P L Olive; R E Durand; K A Krohn
Journal:  Radiat Res       Date:  1987-08       Impact factor: 2.841

Review 5.  Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5.

Authors:  Cameron J Koch
Journal:  Methods Enzymol       Date:  2002       Impact factor: 1.600

6.  Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3.

Authors:  P Mahy; M De Bast; P H Leveque; J Gillart; D Labar; J Marchand; V Gregoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

7.  In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors.

Authors:  Pierre Mahy; Marc De Bast; Bernard Gallez; John Gueulette; Cameron J Koch; Pierre Scalliet; Vincent Grégoire
Journal:  Radiother Oncol       Date:  2003-04       Impact factor: 6.280

8.  Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide].

Authors:  S M Evans; B Joiner; W T Jenkins; K M Laughlin; E M Lord; C J Koch
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640
  8 in total
  9 in total

1.  Imaging of tumour hypoxia using PET and 18F-labelled tracers: biology meets technology.

Authors:  Tove Grönroos; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

2.  Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.

Authors:  Nicolas Christian; Anne Bol; Marc De Bast; Daniel Labar; John Lee; Pierre Mahy; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-03       Impact factor: 9.236

Review 3.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 4.  Molecular imaging of hypoxia with radiolabelled agents.

Authors:  Gilles Mees; Rudi Dierckx; Christel Vangestel; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-30       Impact factor: 9.236

5.  A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.

Authors:  Stéphanie Servagi-Vernat; Sarah Differding; Francois-Xavier Hanin; Daniel Labar; Anne Bol; John A Lee; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-26       Impact factor: 9.236

6.  [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.

Authors:  Ludwig Dubois; Willy Landuyt; Lieselotte Cloetens; Anne Bol; Guy Bormans; Karin Haustermans; Daniel Labar; Johan Nuyts; Vincent Grégoire; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-09       Impact factor: 9.236

Review 7.  Hypoxia in murine atherosclerotic plaques and its adverse effects on macrophages.

Authors:  Saj Parathath; Yuan Yang; Stephanie Mick; Edward A Fisher
Journal:  Trends Cardiovasc Med       Date:  2013-02-01       Impact factor: 6.677

8.  Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism.

Authors:  P Mahy; X Geets; M Lonneux; P Levêque; N Christian; M De Bast; J Gillart; D Labar; J Lee; V Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-04       Impact factor: 9.236

Review 9.  How to Modulate Tumor Hypoxia for Preclinical In Vivo Imaging Research.

Authors:  Sven De Bruycker; Christel Vangestel; Steven Staelens; Tim Van den Wyngaert; Sigrid Stroobants
Journal:  Contrast Media Mol Imaging       Date:  2018-10-18       Impact factor: 3.161
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.